Oncolytics Biotech Inc. (ONCY) intrinsic value & 10-year financials
Oncolytics Biotech Inc. (ONCY) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.50
- Market cap
- $47.7M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 358.1%
- Free cash flow (FY2025)
- -$20.1M
ONCY 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$28.8M | -$0.30 | -$20.1M | — | 362.4% |
| FY2024 | — | -$22.8M | -$0.30 | -$20.1M | — | 353.8% |
| FY2023 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
ONCOLYTICS BIOTECH INC revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
ONCOLYTICS BIOTECH INC has historically struggled to out-earn its cost of capital, averaging just 3.6% ROIC.
ONCOLYTICS BIOTECH INC capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
ONCOLYTICS BIOTECH INC is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.